Skip to main content

How does Zinbryta work?

Medically reviewed by Judith Stewart, BPharm. Last updated on March 1, 2024.

Official answer

by Drugs.com

Zinbryta (daclizumab) is an interleukin-2 receptor blocking antibody for the treatment of adults with relapsing forms of multiple sclerosis (MS). It is thought to work by decreasing T-cells and pro-inflammatory lymphoid tissue inducer cells, and increasing CD56bright natural killer (NK) cells, important cells that help regulate the immune system.

Zinbryta should only be used in patients who have had an inadequate response to two or more multiple sclerosis drugs.

The Zinbryta product label carries a boxed warning advising the serious safety risks, including liver injury and immune disorders.

Zinbryta is available only through a restricted distribution program under a Risk Evaluation and Mitigation Strategy.

In March 2018, Biogen and AbbVie announced the voluntary worldwide withdrawal of Zinbryta.

Read next

Multiple sclerosis (MS) is not generally considered life-threatening and most people will live a normal life-span. One study has found that the average life expectancy for people with MS is 76 years of age. In 2019, the U.S. life-expectancy averaged 78.8 years, but in 2020 it declined to 77.3 years, primarily due to the COVID pandemic. Many people with MS may live for 25 to 35 years or longer after their diagnosis. Continue reading

Some of the early signs of multiple sclerosis (MS) include weakness or numbness in one or more limbs; tremor or abnormal, uncoordinated movements while walking; slurred speech, or dizziness; double vision or the painful loss of vision in one eye; or long-lasting fatigue. Continue reading

Prednisone first came onto the market over sixty years ago and is still going strong. But did you know that this common drug used for a variety of different conditions also has some pretty serious side effects as well? Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer